Auxilium Xiaflex likely to be approved, says Stifel Stifel thinks there is at least an 80% chance that Auxilium's Xiaflex for Peyronie’s disease will be approved by the FDA. Noting that the drug has a December 6 PDUFA date, Stifel believes the stock can "trade well into the mid-$20s" if the drug is approved. The firm keeps a Buy rating on the stock.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.